Table 3 Estimated effect (EE) and effect size (ES) of early engagement in Learning Collaboratives
| Â | Early engagement with a prescriber vs. Early engagement without a prescriber | ||
|---|---|---|---|
Q1 | Q2 | Q3 | |
Reach | |||
 Number of patients with OUD | |||
  EE (95% CI) | 22.77 (−1441.20, 1486.74) | 8.82 (−696.67, 714.31) | −5.13 (−1468.98, 1458.72) |
  ES (95% CI) | 0.32 (−20.34, 20.99) | 0.12 (−9.83, 10.08) | −0.07 (−20.74, 20.59) |
 Number of patients prescribed MOUD | |||
  EE (95% CI) | 6.19 (−47.23, 59.60) | 1.97 (−34.05, 38.00) | −2.25 (−55.66, 51.17) |
  ES (95% CI) | 0.37 (−2.79, 3.53) | 0.12 (−2.02, 2.25) | −0.13 (−3.29, 3.03) |
 Percent of patients prescribed MOUDa | |||
  EE (95% CI) | −8.02 (−12.83, −3.20) | 0.31 (−3.59, 4.22) | 8.65 (1.39, 15.90) |
  ES (95% CI) | −0.22 (−0.36, −0.09) | 0.01 (−0.10, 0.12) | 0.24 (0.04, 0.44) |
Adoption | |||
 Number of prescribers | |||
  EE (95% CI) | 0.35 (−3.99, 4.68) | 1.37 (−2.41, 5.15) | 2.40 (−1.93, 6.73) |
  ES (95% CI) | 0.08 (−0.89, 1.04) | 0.31 (−0.54, 1.15) | 0.54 (−0.43, 1.50) |
 Number of x-waivered prescribers | |||
  EE (95% CI) | 0.29 (−1.47, 2.05) | 0.75 (−0.76, 2.26) | 1.21 (−0.54, 2.97) |
  ES (95% CI) | 0.10 (−0.51, 0.71) | 0.26 (−0.26, 0.79) | 0.42 (−0.19, 1.03) |
 Number of active x-waivered prescribers | |||
  EE (95% CI) | 0.36 (−0.28, 1.00) | 0.73 (0.22, 1.25) | 1.10 (0.46, 1.74) |
  ES (95% CI) | 0.20 (−0.16, 0.55) | 0.40 (0.12, 0.69) | 0.61 (0.25, 0.96) |
 Percent of x-waivered prescribers | |||
  EE (95% CI) | −1.73 (−2.76, −0.70) | −1.94 (−2.85, −1.02) | −2.14 (−3.18, −1.11) |
  ES (95% CI) | −0.08 (−0.13, −0.03) | −0.09 (−0.13, −0.05) | −0.10 (−0.14 −0.05) |
Implementation quality | |||
 IMAT implementation quality | |||
  EE (95% CI) | – | – | 0.33 (0.25, 0.42) |
  ES (95% CI) | – | – | 0.55 (0.41, 0.69) |